Publication details

Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic

Authors

SKŘIČKOVÁ Jana BORTLÍČEK Zbyněk HEJDUK Karel PEŠEK Miloš KOLEK Vítězslav KOUBKOVÁ Leona TOMÍŠKOVÁ Marcela ŠATÁNKOVÁ Monika POVOLNÁ Zdenka ČOUPKOVÁ Helena HAVEL Libor ZEMANOVÁ Milada SIXTOVÁ Dimka SALAJKA František HRNČIARIK Michal ČERNOVSKÁ Markéta

Year of publication 2013
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description In a group of 74 patients with advanced NSCLC and with activated mutations v/ho were treated with gefitinib in first line, the therapy was well tolerated, median progression-free survival from gefitinib treatment initiation is 8.1 months (95% CI: 6.9; 9.3) and median overall survival (OS) was not reached.

You are running an old browser version. We recommend updating your browser to its latest version.

More info